Profilo
Bruce Hovanes worked as a Director at the Biotechnology Association of Alabama, Vice President-Administration at Egen, Inc., and VP-Administration & Information Technology at Shearwater Corp.
from 1992 to 2002.
Precedenti posizioni note di Bruce Hovanes
Società | Posizione | Fine |
---|---|---|
Shearwater Corp.
Shearwater Corp. Pharmaceuticals: MajorHealth Technology Part of Nektar Therapeutics, Shearwater Corp. is a company that provides research services focused on health care applications of advanced PEGylation. The company is based in Huntsville, AL. The company was founded by James R. Hudson, J. Milton Harris. Shearwater was acquired by Nektar Therapeutics on July 02, 2001 for $164.50 million. | Direttore Amministrativo | - |
Biotechnology Association of Alabama
Biotechnology Association of Alabama Miscellaneous Commercial ServicesCommercial Services The Biotechnology Association of Alabama is a leading advocate for the state's bioeconomy. The private company is based in Birmingham, AL. The company represents the state on a national and international stage, promoting the intellectual and innovative capital that make Alabama a premier place to invest, start, and grow in bioscience. The company was founded by Thomas P. Dooley. | Direttore/Membro del Consiglio | - |
Egen, Inc.
Egen, Inc. Medical SpecialtiesHealth Technology Egen, Inc. operates as a clinical stage biopharmaceutical company which develops novel proprietary nanoparticle delivery technology for therapeutic use. Egen's technology platform is very broad, including polymer, cationic lipid, and molecular biology-based approaches to delivery of nucleic acid and anti-cancer drugs. The primary activities of the company are the application of the TheraPlas and TheraSilence platforms to the treatment of human disease. Egen's lead candidate, EGEN-001, is in Phase II clinical testing for ovarian cancer and in Phase I clinical testing for colorectal cancer. In addition, Egen is pursuing pre-clinical development of its TheraSilence RNAi delivery program for multiple disease applications, as well as other novel disruptive technologies focused on creating the next generation of synthetic nanoparticle delivery systems and nucleic acid-based therapies. It is also active in pursuing partnerships and working with external collaborators to further develop its delivery technology for multiple applications. Egen offers cutting-edge research services relating to non-viral polymeric gene carrier systems, and other approaches for the delivery of nucleic acid and anti-cancer drugs. The company's synthetic biocompatible delivery vehicles can be used to deliver therapeutic genes, inhibitory RNA (RNAi), and small molecules by protecting the therapeutic cargo from degradation, promoting uptake by target cells, and facilitating intracellular trafficking. Egen was founded in 2002 by Sung Wan Kim and is headquartered in Huntsville, AL. | Direttore Amministrativo | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 3 |
---|---|
Egen, Inc.
Egen, Inc. Medical SpecialtiesHealth Technology Egen, Inc. operates as a clinical stage biopharmaceutical company which develops novel proprietary nanoparticle delivery technology for therapeutic use. Egen's technology platform is very broad, including polymer, cationic lipid, and molecular biology-based approaches to delivery of nucleic acid and anti-cancer drugs. The primary activities of the company are the application of the TheraPlas and TheraSilence platforms to the treatment of human disease. Egen's lead candidate, EGEN-001, is in Phase II clinical testing for ovarian cancer and in Phase I clinical testing for colorectal cancer. In addition, Egen is pursuing pre-clinical development of its TheraSilence RNAi delivery program for multiple disease applications, as well as other novel disruptive technologies focused on creating the next generation of synthetic nanoparticle delivery systems and nucleic acid-based therapies. It is also active in pursuing partnerships and working with external collaborators to further develop its delivery technology for multiple applications. Egen offers cutting-edge research services relating to non-viral polymeric gene carrier systems, and other approaches for the delivery of nucleic acid and anti-cancer drugs. The company's synthetic biocompatible delivery vehicles can be used to deliver therapeutic genes, inhibitory RNA (RNAi), and small molecules by protecting the therapeutic cargo from degradation, promoting uptake by target cells, and facilitating intracellular trafficking. Egen was founded in 2002 by Sung Wan Kim and is headquartered in Huntsville, AL. | Health Technology |
Shearwater Corp.
Shearwater Corp. Pharmaceuticals: MajorHealth Technology Part of Nektar Therapeutics, Shearwater Corp. is a company that provides research services focused on health care applications of advanced PEGylation. The company is based in Huntsville, AL. The company was founded by James R. Hudson, J. Milton Harris. Shearwater was acquired by Nektar Therapeutics on July 02, 2001 for $164.50 million. | Health Technology |
Biotechnology Association of Alabama
Biotechnology Association of Alabama Miscellaneous Commercial ServicesCommercial Services The Biotechnology Association of Alabama is a leading advocate for the state's bioeconomy. The private company is based in Birmingham, AL. The company represents the state on a national and international stage, promoting the intellectual and innovative capital that make Alabama a premier place to invest, start, and grow in bioscience. The company was founded by Thomas P. Dooley. | Commercial Services |
- Borsa valori
- Insiders
- Bruce Hovanes